{"id":"https://openalex.org/W46526311","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3057","title":"Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors","display_name":"Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W46526311","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3057","mag":"46526311"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.3057","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3057","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.3057","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102964486","display_name":"George R. Simon","orcid":"https://orcid.org/0000-0002-3894-0773","observed_orcids":["https://orcid.org/0000-0002-3894-0773"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. R. Simon","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Olson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Olson","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049076838","display_name":"Chris R. Garrett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. R. Garrett","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039144013","display_name":"Irene A. Eiseman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Eiseman","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113657238","display_name":"Michael Langevin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Langevin","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057204740","display_name":"John J. Mahany","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. J. Mahany","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. M. Sullivan","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024946496","display_name":"Michael Schlicht","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. G. Schlicht","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111718623","display_name":"Richard M. Lush","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Lush","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004546542","display_name":"P. Lanehan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Lanehan","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Pfizer Global R&D, Ann Arbor, MI","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"3057","last_page":"3057"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.008200000040233135,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ci-1033","display_name":"CI-1033","score":0.9950000047683716},{"id":"https://openalex.org/keywords/eribulin","display_name":"eribulin","score":0.6010000109672546},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.828000009059906},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.871999979019165},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7680000066757202},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.7599999904632568},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8140000104904175},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6819999814033508},{"id":"https://openalex.org/keywords/non-hematologic-malignancies","display_name":"non-hematologic malignancies","score":0.7059999704360962},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.46299999952316284},{"id":"https://openalex.org/keywords/mesothelioma","display_name":"mesothelioma","score":0.8539999723434448},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.9359999895095825},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8130000233650208}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9104211926460266},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6251921057701111},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6146287322044373},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6119526028633118},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5704972743988037},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5699807405471802},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5665080547332764},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48642754554748535},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.41855859756469727},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.41538581252098083},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3242132365703583},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.2784445583820343}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.3057","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3057","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.3057","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.3057","doi":"https://doi.org/10.1200/jco.2004.22.90140.3057","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.3057","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2099245955","https://openalex.org/W2141937666","https://openalex.org/W2243646131","https://openalex.org/W2157013824","https://openalex.org/W1982159091","https://openalex.org/W4214703349","https://openalex.org/W2156509877","https://openalex.org/W2126779285","https://openalex.org/W2899889756","https://openalex.org/W2065136060"],"abstract_inverted_index":{"3057":[0],"Background:":[1],"CI-1033":[2,44,137,309],"is":[3,310,331],"a":[4,52,99,108,224],"pan-erbB":[5],"tyrosine":[6],"kinase":[7],"inhibitor.":[8],"In":[9],"phase":[10,222,234],"1":[11,63],"oral":[12],"(PO)":[13],"studies,":[14],"dose":[15,214],"limiting":[16],"toxicities":[17],"were":[18,59,122,155,188,202,280],"primarily":[19],"gastrointestinal":[20],"(GI),":[21],"which":[22],"supported":[23],"the":[24,147,184,191,231,303,322,328],"exploration":[25],"of":[26,135,146,181,198,242,308,321],"IV":[27,43,105,128,154,192,205,275,284,304,316,329],"dosing":[28,134,285,289],"to":[29,101,114,194,226,287,333],"achieve":[30],"higher":[31,296,323],"drug":[32,297,324],"exposures.":[33],"Methods:":[34],"Forty-eight":[35],"patients":[36],"(pts)":[37],"with":[38,126,131,170,216],"advanced":[39],"nonhematologic":[40],"malignancies":[41],"received":[42],"via":[45],"30":[46],"min":[47],"infusions":[48],"(10\u2013500":[49],"mg)":[50],"on":[51,61,183],"3-day":[53],"weekly":[54,133],"(MWF)":[55],"schedule.":[56],"PK":[57],"samples":[58],"collected":[60],"Days":[62],"and":[64,66,107,167,206,294],"8":[65],"evaluated":[67],"using":[68],"compartmental":[69],"analysis":[70],"(NONMEM":[71],"ADVAN3).":[72],"Results:":[73],"28M/20F,":[74],"ECOG":[75],"PS":[76],"0":[77],"&":[78],"1,":[79],"median":[80],"age":[81],"54":[82],"(42\u201373),":[83],"tumors:":[84],"lung":[85],"11,":[86],"colorectal":[87],"10,":[88],"mesothelioma":[89],"9,":[90],"melanoma":[91],"4,":[92],"unknown":[93],"primary":[94],"2,":[95],"others":[96],"12.":[97],"Despite":[98],"5":[100],"10-fold":[102],"increase":[103,110],"in":[104,111,179,190,273],"Cmax":[106],"3-fold":[109],"AUC":[112],"compared":[113],"PO":[115,136,171,185,207,288],"at":[116,254,290],"equivalent":[117],"doses,":[118],"treatment-related":[119],"GI":[120,150,176],"AEs":[121,151,177,279],"notably":[123],"less":[124,281],"frequent":[125,282],"this":[127,274],"regimen":[129],"than":[130],"once":[132],"(100\u20131000":[138],"mg;":[139],"n=55;":[140],"Proc.":[141],"ASCO":[142],"2001,283:72a).":[143],"The":[144,196,219,318],"incidences":[145,197],"most":[148],"common":[149],"when":[152],"given":[153],"Gr":[156,174,199],"1\u20132":[157],"nausea":[158],"(15%),":[159],"vomiting":[160],"(11%),":[161],"diarrhea":[162],"(7%)":[163],"vs":[164],"60%,":[165],"40%,":[166],"49%,":[168],"respectively,":[169],"dosing.":[172,317],"Whereas":[173],"3":[175,200,227,238,255],"occurred":[178],"2%":[180],"pts":[182],"study,":[186],"none":[187],"reported":[189],"study":[193],"date.":[195],"hypersensitivity":[201],"comparable":[203,291],"for":[204],"regimens":[208],"(each":[209],"2%).":[210],"Systemic":[211,250,257],"exposure":[212,258],"was":[213,236,252,259],"proportional":[215],"bi-phasic":[217],"elimination.":[218],"initial":[220],"distribution":[221,243],"had":[223],"2":[225],"minute":[228],"half-life":[229,235],"while":[230],"terminal":[232],"elimination":[233],"approx":[237],"hrs.":[239],"Central":[240],"volume":[241],"(18.5":[244],"liters)":[245],"approximated":[246],"extravascular":[247],"water":[248],"volume.":[249],"clearance":[251],"rapid":[253],"L/min.":[256],"not":[260],"dependent":[261],"upon":[262],"age,":[263],"gender,":[264],"race,":[265],"renal":[266],"function,":[267],"body":[268],"weight":[269],"or":[270,343,346],"surface":[271],"area":[272],"study.":[276],"Conclusions:":[277],"Gastrointestinal":[278],"following":[283,315],"relative":[286],"systemic":[292],"exposures":[293,298,325],"hence":[295],"could":[299],"be":[300,334],"acheived":[301],"by":[302,327],"route.":[305],"Oral":[306],"bioavailability":[307],"about":[311],"one-third":[312],"that":[313],"observed":[314],"clinical":[319],"significance":[320],"achieved":[326],"route":[330],"yet":[332],"determined":[335],"but":[336],"warrants":[337],"further":[338],"investgation.":[339],"Author":[340],"Disclosure":[341],"Employment":[342],"Leadership":[344],"Consultant":[345],"Advisory":[347],"Stock":[348],"Ownership":[349],"Honoraria":[350],"Research":[351],"Funding":[352],"Expert":[353],"Testimony":[354],"Other":[355],"Remuneration":[356],"Pfizer":[357,358,359,360]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}